FDA Drug Review Deal Set to Unravel as Fiscal Cliff Looms

A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.